Promoter buys 60,000 shares of Goldline Pharmaceutical via open market

Promoter Stake BuyOwnership Changes View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Next day

₹41.00

prior close

—

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.0%-0.3% vs market

Pharmaceuticals peers, median of 172sector+0.3%-0.5% vs sector

By the next day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

—-0.6—-0.2—

Next day

-0.2+0.0-0.3+0.3-0.5

-4.1+0.7-4.8+0.2-4.3

-7.3+1.1-8.4+0.6-7.9

-9.0+1.6-10.7+0.8-9.8

-7.3+1.5-8.8+0.1-7.4

-11.0+1.4-12.4+0.6-11.5

15d

-20.7+0.4-21.2+0.8-21.6

—-1.4—-2.0—

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mr. Amol Mujumdar, Promoter and Managing Director of Goldline Pharmaceutical, bought 60,000 equity shares (0.62%) through open market on 31 Aug 2026. His stake rose from 28.64% (27,49,988 shares) to 29.27% (28,09,988 shares). Filing made under SEBI SAST Regulation 29(2).

Likely market impact

Promoter confidence signal as insider increases open market stake, pushing holding closer to 30 percent mark.